StockData

Amylyx Pharmaceuticals vs Septerna

AMLX and SEPN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMLX and SEPN compare

Amylyx Pharmaceuticals is the larger company, worth 1.6 times as much as Septerna ($3.1B against $1.9B).

Septerna scores higher on the StockData Score (8 against 6 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMLXSEPN
Size and price
Market cap$3.1B$1.9B
Share price$27.52$40.02
Change, 1 year117%72.0%
Change, 5 years168%–
Beta (5Y)0.540.70
Employees136130
StockData Score
Total score68 (better)
Valuation score00
Growth score01 (better)
Performance score01 (better)
Health score66
Dividend score00
Valuation
P/S–19.4×
P/B12.8×4.4× (better)
FCF yield–−4.2%
Fair value–$15.08
Margin of safety–−165%
Growth
Revenue growth (TTM)–337%
Profitability
Operating margin–−76.2%
Net margin–−61.3%
FCF margin–−80.6%
Return on equity−74.7%−14.4% (better)
Financial health
Debt / equity0.000.00
Current ratio12.12 (better)4.84
Altman Z-score67.06 (better)5.91
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions104%102%
Held by insiders7.8%27.9%
Insider net buying, 12 months−$17.2M (better)−$80.9M
Short interest, % of float12.5%10.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.